Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
RESEARCH TOOLSreports
NMRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $21.00
Previous CloseN/A
Volume2.95M
Average Volume (3M)3.19M
Market Cap
$279.50M
Enterprise Value$1.77B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Mar 03, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding161,561,070
10 Day Avg. Volume1,674,888
30 Day Avg. Volume3,185,741
Standard Deviation0.29
R-Squared0.09
Alpha-0.11
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap6.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.65K
Enterprise Value/Ebitda-5.89
Forecast
1Y Price Target
$16.80Price Target Upside912.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Neumora Therapeutics, Inc. News
PremiumCompany Announcements
Neumora Therapeutics Announces Leadership Changes and Strategy
PremiumCompany Announcements
Neumora Therapeutics Highlights Progress at Healthcare Conference
---
Bulls Say, Bears Say
Bulls Say
LeadershipThe return of Paul Berns as CEO is expected to reinvigorate the company's focus on research and development, potentially advancing its pipeline.
Product PotentialThe potential of navacaprant, a novel kappa opioid receptor antagonist, in treating major depressive disorder has been highlighted as promising by a key opinion leader.
Trial SuccessSafety and tolerability for navacaprant have been excellent so far, with no significant side effects reported, which is considered ideal for trial success.
Bears Say
Product ValidationNavacaprant's mechanism of action has yet to be fully validated in major depressive disorder, leading to a model probability of success of 50%.
Regulatory ApprovalThere are risks associated with regulatory approval, as none of Neumora's products have been approved by the FDA.
Trial ResultsNMRA announced negative first P3 KOASTAL-1/K-1 study data for navacaprant in major depressive disorder, with navacaprant missing on both primary and secondary endpoints.
---
Ownership Overview
26.13% Insiders
8.59% Mutual Funds
33.19% Other Institutional Investors
26.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $1.60 and its highest was $21.00 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $279.50M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Mar 03, 2025 which is in 10 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.059.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 161,561,070 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went down -17.082%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
---
Neumora Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.80 (912.05% Upside)
$16.80 (912.05% Upside)
Blogger Sentiment
Neutral
NMRA Sentiment 50%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.59%
12-Months-Change
Fundamentals
Return on Equity
-70.48%
Trailing 12-Months
Asset Growth
-35.28%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
---
NMRA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Neumora's robust clinical pipeline and financial position, with promising developments in their lead program, Navacaprant. However, increased operating expenses and the inherent challenges in CNS drug development were noted.Read More>---
NMRA Stock 12 Month Forecast
Average Price Target
$16.80
▲(912.05% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Vertex Pharmaceuticals
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering NMRA
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-45.48%
reiterated a buy rating 2 months ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -45.48% per trade.
---